Endothelial progenitor cells are associated with response to chemotherapy in human non-small-cell lung cancer

Morita, Ryo; Sato, Kazuhiro; Nakano, Mariko; Miura, Hiroyuki; Odaka, Hidesato; Nobori, Kiyoshi; Kosaka, Toshimitsu; Sano, Mitsuru; Watanabe, Hiroyuki; Shioya, Takanobu; Ito, Hiroshi

doi:10.1007/s00432-011-1043-8

Cited by 18 publications

(9 citation statements)

References 30 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, patients with a high CEC count at baseline had a significantly worse PFS and OS. A majority of reports showed that high baseline CEC levels above the 75th percentile significantly correlated with prognosis, and could be useful as prognostic markers in patients with advanced NSCLC (Fleitas et al , 2010; Morita et al , 2011; Wang et al , 2013). In contrast, a study of 31 patients with advanced NSCLC treated with first-line carboplatin and paclitaxel reported that a CEC count of >400/4 ml at baseline showed a significantly improved PFS.…”

Section: Discussionmentioning

confidence: 99%

Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer

et al. 2014

View full text Add to dashboard Cite

Background:Previous studies indicate that endothelial injury, as demonstrated by the presence of circulating endothelial cells (CECs), may predict clinical outcome in cancer patients. In addition, soluble CD146 (sCD146) may reflect activation of angiogenesis. However, no study has investigated their combined clinical value in patients undergoing resection for non-small cell lung cancer (NSCLC).Methods:Data were collected from preoperative blood samples from 74 patients who underwent resection for NSCLC. Circulating endothelial cells were defined, using the CellSearch Assay, as CD146+CD105+CD45−DAPI+. In parallel, sCD146 was quantified using an ELISA immunoassay. These experiments were also performed on a group of 20 patients with small-cell lung cancer, 60 healthy individuals and 23 patients with chronic obstructive pulmonary disease.Results:The CEC count and the plasma level of sCD146 were significantly higher in NSCLC patients than in the sub-groups of controls (P<0.001). Moreover, an increased CEC count was associated with higher levels of sCD146 (P=0.010). Both high CEC count and high sCD146 plasma level at baseline significantly correlated with shorter progression-free survival (P<0.001, respectively) and overall survival (P=0.005; P=0.009) of NSCLC patients.Conclusions:The present study provides supportive evidence to show that both a high CEC count and a high sCD146 level at baseline correlate with poor prognosis and may be useful for the prediction of clinical outcome in patients undergoing surgery for NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In situ hybridization demonstrated that CXCR7 mRNA was confined to the vascular endothelium at the depths of glial cell tumours, where CXCL12 was concentrated (Odemis et al, 2012). Furthermore, CXCR7 plays an important role in human cord blood derived EPCs in response to CXCL12 by inducing EPCs adhesion to active umbilical vein endothelial cells and trans-endothelial migration (Burns et al, 2006;Morita et al, 2011;Tseng et al, 2011). In the present study, CXCR7 mRNA was detected in hemangioblastoma, but significantly lower than that in brain tissues from patients with neurilemmoma or meningioma, which was not found before.…”

Section: Discussionmentioning

confidence: 99%

“…Macrophage migration inhibitory factor (MIF), which is secreted by rhabdomyosarcoma (RMS), is an autocrine/ paracrine factor that interacts with CXCR4 as well as with CXCR7 to enhance the adhesiveness of RMS cells (Tarnowski et al, 2010). EPCs may offer a possible biomarker for efficient of treatment and prognosis (Morita et al, 2011). Specifically, CXCR7 makes it easier for EPC promoters to stay on the endothelium, to penetrate the area of angiogenesis, and to enhance the stability of the extracellular matrix.…”

Section: Introductionmentioning

confidence: 99%

Expression of the CXCL12/SDF-1 Chemokine Receptor CXCR7 in Human Brain Tumours

Tang¹,

Xia²,

Chen³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Purpose: Receptor 7 (CXCR7) has recently been characterized as a novel receptor for CXCL12/SDF-1 (stromal cell derived factor-1). Given the demonstrated importance of CXCL12/SDF-1 in angiogenesis and tumour metastasis, we hypothesized that CXCR7 may also play a role in tumour pathogenesis. Located in the limited space of the intracranial cavity, any brain tumours can be inherently serious and life-threatening. However, the expression of CXCR7 in pituitary adenoma, neurilemmoma or hemangioblastoma remains to be elucidated. Therefore, we aimed to determine the potential contribution of CXCR7 in the development of brain tumours. Methods: In this study we examined and quantified the mRNA expression of CXCR7 in four different human brain tumours -27 patients with neurilemmoma (8 patients), pituitary adenoma (7 patients), hemangioblastoma (6 patients), or meningioma (6 patients) undergoing surgical resection in the West China Hospital of Sichuan University. There were 15 females and 12 males aged from 28 to 70 years old. Total RNA was isolated and mRNA was measured by quantitative real-time RT-PCR. One-way analysis of variance (ANOVA) was performed using SPSS 11.0 statistical software to compare the mRNA levels of CXCR7 among four groups. Results: We found that CXCR7 mRNA was detected in all tumour samples. Quantitative results showed that the levels of CXCR7 mRNA in brain tissues from patients with neurilemmoma or meningioma were significantly higher than those with pituitary adenoma or hemangioblastoma. Conclusions: The results suggest that the CXCR7 may play a role in progression, metastasis and angiogenesis of brain tumours.

show abstract

“…6 The numbers of circulating EPCs have been shown to be increased in malignant diseases such as breast cancer, ovarian cancer, nonsmall cell lung cancer and lymphoma. [7][8][9][10][11][12] The kinetics of circulating EPCs and endothelial cells in response to antiangiogenic treatment have been studied in animal models. 2 There is evidence that metronomic chemotherapy and inhibitors of the VEGFR signalling pathway can suppress circulating EPC numbers.…”

Section: Introductionmentioning

confidence: 99%

Circulating endothelial progenitor cells in gynaecological cancer

et al. 2013

View full text Add to dashboard Cite

Objectives: To compare the frequency and absolute numbers of circulating endothelial progenitor cells (EPCs) in healthy control subjects and patients with gynaecological cancer, and to test the hypothesis that cancer treatment lowers EPC numbers. Methods: Patients with cervical or ovarian cancer and healthy control subjects provided peripheral blood samples for the isolation of mononuclear cells. EPCs were identified by quadruple immunofluorescence staining and flow cytometry as CD45

show abstract

Endothelial progenitor cells are associated with response to chemotherapy in human non-small-cell lung cancer

Abstract: Peripheral blood levels of bone marrow-derived EPCs are significantly increased in patients with NSCLC and correlate with response to chemotherapy. EPCs may offer a possible biomarker for efficient of treatment and prognosis.

Cited by 18 publications

References 30 publications

Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer

Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer

Expression of the CXCL12/SDF-1 Chemokine Receptor CXCR7 in Human Brain Tumours

Circulating endothelial progenitor cells in gynaecological cancer

Contact Info

Product

Resources

About